PHARVARIS NV (PHVS) Stock Price, Quote, News and Overview
NASDAQ:PHVS - Nasdaq - NL00150005Y4 - Common Stock - Currency: USD
PHVS Quote, Performance and Key Statistics
PHARVARIS NV
NASDAQ:PHVS (2/10/2025, 8:17:48 PM)
17.855
-0.43 (-2.38%)
The current stock price of PHVS is 17.855 USD. In the past month the price increased by 0.31%. In the past year, price decreased by -33.62%.
PHVS Latest News and Analysis
Pharvaris Outlines 2025 Strategic Priorities
Pharvaris Outlines 2025 Strategic Priorities
Initiated CHAPTER-3, the pivotal Phase 3 study of deucrictibant for prophylaxis against hereditary angioedema (HAE) attacks in 2024; topline data...
Pharvaris Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates
Pharvaris Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates
Positive long-term extension data highlighting the differentiated profile of deucrictibant for the prevention and treatment of HAE attacks presented at...
Pharvaris to Participate in the Guggenheim Healthcare Innovation Conference
Pharvaris to Participate in the Guggenheim Healthcare Innovation Conference
ZUG, Switzerland, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2...
PHVS Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 66.84 | 824.85B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 26.55 | 372.57B | ||
| JNJ | JOHNSON & JOHNSON | 15.44 | 371.35B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 20.13 | 225.33B | ||
| MRK | MERCK & CO. INC. | 11.31 | 218.56B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.63 | 213.62B | ||
| PFE | PFIZER INC | 8.32 | 146.61B | ||
| SNY | SANOFI-ADR | 13.45 | 133.58B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 48.71 | 112.62B | ||
| ZTS | ZOETIS INC | 29.85 | 77.56B | ||
| GSK | GSK PLC-SPON ADR | 7.91 | 74.41B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 30.52 | 42.58B |
Related stock screener links
About PHVS
Company Profile
Pharvaris NV operates as a clinical-stage biopharmaceutical company. The company is headquartered in Leiden, Zuid-Holland and currently employs 82 full-time employees. The company went IPO on 2021-02-05. The activity of the Company focuses on producing oral bradykinin B2-receptor antagonists and is advancing new alternatives to injected therapies for all sub-types of hereditary angioedema (HAE).
Company Info
PHARVARIS NV
J.H. Oortweg 21
Leiden ZUID-HOLLAND NL
CEO: Berndt Modig
Employees: 83
Company Website: https://pharvaris.com/
Investor Relations: http://ir.pharvaris.com
PHVS FAQ
What is the stock price of PHVS?
The current stock price of PHVS is 17.855 USD.
What is the symbol for PHARVARIS NV stock?
The exchange symbol of PHARVARIS NV is PHVS and it is listed on the Nasdaq exchange.
On which exchange is PHVS stock listed?
PHVS stock is listed on the Nasdaq exchange.
Is PHVS a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for PHVS, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of PHVS.
Does PHVS stock pay dividends?
PHVS does not pay a dividend.
What is the Price/Earnings (PE) ratio of PHVS?
PHVS does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.68).
What is the Short Interest ratio of PHVS stock?
The outstanding short interest for PHVS is 0.48% of its float.
PHVS Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to PHVS. When comparing the yearly performance of all stocks, PHVS is a bad performer in the overall market: 88.29% of all stocks are doing better.
PHVS Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to PHVS. While PHVS seems to be doing ok healthwise, there are quite some concerns on its profitability.
PHVS Financial Highlights
Over the last trailing twelve months PHVS reported a non-GAAP Earnings per Share(EPS) of -2.68. The EPS increased by 14.75% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -42.22% | ||
| ROE | -44.55% | ||
| Debt/Equity | 0 |
PHVS Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 84% to PHVS. The Buy consensus is the average rating of analysts ratings from 14 analysts.